What is Amgen's cash & equivalents?

Amgen (AMGN) reported cash & equivalents of $559M in Q1 2026.

How has Amgen's cash & equivalents changed year-over-year?

Amgen's cash & equivalents increased by 10.0% year-over-year, from $508M to $559M.

What is the long-term trend for Amgen's cash & equivalents?

Over 5 years (2020 to 2025), Amgen's cash & equivalents has grown at a -5.5% compound annual growth rate (CAGR), from $802M to $604M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Amgen AMGN Cash & Equivalents

Cash & Equivalents at other companies

Eli LillyLLY

$5.28B+70.8%

PfizerPFE

$1.76B+18.8%

Regeneron PharmaceuticalsREGN

$2.97B-4.0%

Nektar TherapeuticsNKTR

$5.7M-20.0%

Oruka Therapeutics, Inc.ORKA

$49.52M-40.7%

Rigel PharmaceuticalsRIGL

$24.47M-46.6%

Other financials

Income statement

See full

Revenue$8.6B+5.8%

Gross profit$5.9B+13.4%

Operating income$2.7B+126%

Net income$1.8B+5.1%

EPS (diluted)$3.34+4.4%

Balance sheet

See full

Total debt$57.3B-0.1%

Total equity$9.2B+48.1%

Total assets$92.5B+3.5%

Cash flow

See full

Operating cash flow$2.2B+57.4%

CapEx$712.0M+73.2%

Free cash flow$1.5B+50.7%

Valuation

See full

Market cap$202.95B+25.3%

Enterprise value$259.72B+19.3%

P/E26×+1.5×

P/S5.5×+0.8×

Profitability

See full

Gross margin68.3%+5.3pp

Operating margin28.4%+6.6pp

Net margin21%+3.6pp

FCF margin23.1%-8.9pp

Returns & leverage

See full

Return on equity101.3%-4.4pp

Debt / equity6.2×-3.0×

Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:Cash.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amgen's cash & equivalents?: Amgen (AMGN) reported cash & equivalents of $559M in Q1 2026.
How has Amgen's cash & equivalents changed year-over-year?: Amgen's cash & equivalents increased by 10.0% year-over-year, from $508M to $559M.
What is the long-term trend for Amgen's cash & equivalents?: Over 5 years (2020 to 2025), Amgen's cash & equivalents has grown at a -5.5% compound annual growth rate (CAGR), from $802M to $604M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.